Nerve growth factor prevents experimental cisplatin neuropathy

Stuart C. Apfel, Joseph C. Arezzo, Leeanne Lipson, John A. Kessler

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Cisplatin is a widely used antitumor agent, the dose-limiting toxicity of which is predominantly large-fiber sensory neuropathy. Prevention of such a neuropathy would extend the usefulness of this agent, allowing higher doses and longer periods of treatment. We report here that we have successfully established cisplatin neuropathy in mice measured by using behavioral, biochemical, and electrophysiological techniques, and that subcutaneous administration of human recombinant nerve growth factor (NGF) prevents or delays the neuropathy. Cisplatin administration reduced sensory ganglion levels of the peptide transmitter, calcitonin gene-related peptide, slowed nerve conduction in the tail and impaired proprioception as measured by the ability to balance on a rotating dowel. NGF coadministration appeared to prevent all these abnormalities. Treatment of the human toxic neuropathy with its well-established time of onset, simple clinical course, and the accessibility of nerve to NGF administered systemically may provide the best clinical setting for the first human trials of NGF.

Original languageEnglish (US)
Pages (from-to)76-80
Number of pages5
JournalAnnals of Neurology
Volume31
Issue number1
StatePublished - Jan 1992

Fingerprint

Nerve Growth Factor
Cisplatin
Sensory Ganglia
Proprioception
Aptitude
Calcitonin Gene-Related Peptide
Poisons
Neural Conduction
Antineoplastic Agents
Tail
Peptides
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Apfel, S. C., Arezzo, J. C., Lipson, L., & Kessler, J. A. (1992). Nerve growth factor prevents experimental cisplatin neuropathy. Annals of Neurology, 31(1), 76-80.

Nerve growth factor prevents experimental cisplatin neuropathy. / Apfel, Stuart C.; Arezzo, Joseph C.; Lipson, Leeanne; Kessler, John A.

In: Annals of Neurology, Vol. 31, No. 1, 01.1992, p. 76-80.

Research output: Contribution to journalArticle

Apfel, SC, Arezzo, JC, Lipson, L & Kessler, JA 1992, 'Nerve growth factor prevents experimental cisplatin neuropathy', Annals of Neurology, vol. 31, no. 1, pp. 76-80.
Apfel, Stuart C. ; Arezzo, Joseph C. ; Lipson, Leeanne ; Kessler, John A. / Nerve growth factor prevents experimental cisplatin neuropathy. In: Annals of Neurology. 1992 ; Vol. 31, No. 1. pp. 76-80.
@article{17ef6654b40f41cbb3af5e6c79f53f4c,
title = "Nerve growth factor prevents experimental cisplatin neuropathy",
abstract = "Cisplatin is a widely used antitumor agent, the dose-limiting toxicity of which is predominantly large-fiber sensory neuropathy. Prevention of such a neuropathy would extend the usefulness of this agent, allowing higher doses and longer periods of treatment. We report here that we have successfully established cisplatin neuropathy in mice measured by using behavioral, biochemical, and electrophysiological techniques, and that subcutaneous administration of human recombinant nerve growth factor (NGF) prevents or delays the neuropathy. Cisplatin administration reduced sensory ganglion levels of the peptide transmitter, calcitonin gene-related peptide, slowed nerve conduction in the tail and impaired proprioception as measured by the ability to balance on a rotating dowel. NGF coadministration appeared to prevent all these abnormalities. Treatment of the human toxic neuropathy with its well-established time of onset, simple clinical course, and the accessibility of nerve to NGF administered systemically may provide the best clinical setting for the first human trials of NGF.",
author = "Apfel, {Stuart C.} and Arezzo, {Joseph C.} and Leeanne Lipson and Kessler, {John A.}",
year = "1992",
month = "1",
language = "English (US)",
volume = "31",
pages = "76--80",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Nerve growth factor prevents experimental cisplatin neuropathy

AU - Apfel, Stuart C.

AU - Arezzo, Joseph C.

AU - Lipson, Leeanne

AU - Kessler, John A.

PY - 1992/1

Y1 - 1992/1

N2 - Cisplatin is a widely used antitumor agent, the dose-limiting toxicity of which is predominantly large-fiber sensory neuropathy. Prevention of such a neuropathy would extend the usefulness of this agent, allowing higher doses and longer periods of treatment. We report here that we have successfully established cisplatin neuropathy in mice measured by using behavioral, biochemical, and electrophysiological techniques, and that subcutaneous administration of human recombinant nerve growth factor (NGF) prevents or delays the neuropathy. Cisplatin administration reduced sensory ganglion levels of the peptide transmitter, calcitonin gene-related peptide, slowed nerve conduction in the tail and impaired proprioception as measured by the ability to balance on a rotating dowel. NGF coadministration appeared to prevent all these abnormalities. Treatment of the human toxic neuropathy with its well-established time of onset, simple clinical course, and the accessibility of nerve to NGF administered systemically may provide the best clinical setting for the first human trials of NGF.

AB - Cisplatin is a widely used antitumor agent, the dose-limiting toxicity of which is predominantly large-fiber sensory neuropathy. Prevention of such a neuropathy would extend the usefulness of this agent, allowing higher doses and longer periods of treatment. We report here that we have successfully established cisplatin neuropathy in mice measured by using behavioral, biochemical, and electrophysiological techniques, and that subcutaneous administration of human recombinant nerve growth factor (NGF) prevents or delays the neuropathy. Cisplatin administration reduced sensory ganglion levels of the peptide transmitter, calcitonin gene-related peptide, slowed nerve conduction in the tail and impaired proprioception as measured by the ability to balance on a rotating dowel. NGF coadministration appeared to prevent all these abnormalities. Treatment of the human toxic neuropathy with its well-established time of onset, simple clinical course, and the accessibility of nerve to NGF administered systemically may provide the best clinical setting for the first human trials of NGF.

UR - http://www.scopus.com/inward/record.url?scp=0026515611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026515611&partnerID=8YFLogxK

M3 - Article

C2 - 1543351

AN - SCOPUS:0026515611

VL - 31

SP - 76

EP - 80

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -